What is Emboline?
Founded in 2011, Emboline specializes in the development of advanced embolic protection systems, most notably the Emboliner Embolic Protection Catheter. The company addresses a significant clinical need by providing comprehensive protection for the cerebral system during TAVR and other high-risk interventional procedures. By capturing both cerebral and non-cerebral debris, Emboline distinguishes itself as a leader in vascular safety technology. Its intellectual property, rooted in the inventions of Amir Belson, positions the firm at the intersection of medical device engineering and patient-centric healthcare solutions, effectively mitigating procedural risks in complex cardiovascular surgeries.
How much funding has Emboline raised?
Emboline has raised a total of $80M across 4 funding rounds:
Series B
$10M
Other Financing Round
$5M
Series C
$10M
Series D
$55M
Series B (2018): $10M with participation from ShangBay Capital and SV Tech Ventures
Other Financing Round (2020): $5M led by Undisclosed
Series C (2021): $10M, investors not publicly disclosed
Series D (2021): $55M featuring Matrix Capital Management, ShangBay Capital, Global Assets Investment, and SV Tech
Key Investors in Emboline
Matrix Capital Management
Matrix Capital Management Company is an investment fund focused on technology and life sciences headquartered in Waltham, Massachusetts.
ShangBay Capital
ShangBay Capital is a venture capital company specializing in medical devices, biotechnology, healthcare, and early-stage industries.
SV Tech
SVTECH is a leading system integration company providing complex IT products and solutions with a focus on large-scale technological projects.
What's next for Emboline?
With the recent influx of capital, Emboline is well-positioned to accelerate its commercialization strategy and expand its footprint in the global medical device market. The company's roadmap likely involves scaling manufacturing capabilities to meet anticipated demand for the Emboliner, alongside ongoing clinical validation to solidify its market position. As the firm moves beyond its current development stage, stakeholders will be monitoring the integration of its technology into standard clinical workflows, which could serve as a catalyst for further institutional backing or potential strategic partnerships within the broader healthcare technology ecosystem.
See full Emboline company page
